restructuring were the decisions to discontinue further development of
ANA380, a nucleotide analog for the treatment of hepatitis B virus
(HBV) infection, halt all work on early discovery projects, and effect
an immediate reduction in force of approximately one-third of the
Company's employees, with several additional positions to be eliminated
in early 2008.
Recent Scientific Presentations
-- Reported ANA773 Dose Schedule Data. On October 25, 2007, Anadys
presented preclinical data on ANA773 during a poster session at the
2007 AACR-NCI-EORTC International Conference on Molecular Targets and
Cancer Therapeutics. The report showed the impact that varying the
dosing schedule has on the pharmacodynamic response to ANA773, a
prodrug of a toll-like receptor 7 agonist. Specifically, the report
described that immunostimulatory responses to ANA773 in vivo can be
modulated by schedule of administration.
-- Reported ANA598 Preclinical Data. On September 11, 2007, Anadys
presented preclinical data on ANA598, a non-nucleoside inhibitor of the
HCV NS5B polymerase, during a poster session at the 14th International
Symposium on Hepatitis C Virus and Related Viruses. The report
characterized the favorable antiviral, metabolic, pharmacokinetic and
preliminary toxicologic properties that supported the decision
announced in June to progress ANA598 to IND enabling studies and
subsequent clinical evaluation expected to commence in the second
quarter of 2008.
Webcast of Conference Call
Anadys will host a conference call today at 5:00 p.m. Eastern Daylight
Time to discuss its third quarter financial results and operational
highlights and to give an update on its programs. A live webcast of the
call will be available online at '/>"/>
|SOURCE Anadys Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved